Private Asset Management Inc. trimmed its position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 99.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 572 shares of the company’s stock after selling 176,448 shares during the period. Private Asset Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $572,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Capital Research Global Investors boosted its stake in shares of Teva Pharmaceutical Industries by 13.8% in the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after purchasing an additional 9,260,426 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 11.1% in the 2nd quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after purchasing an additional 6,685,844 shares in the last quarter. FMR LLC boosted its stake in shares of Teva Pharmaceutical Industries by 16.7% in the 2nd quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after purchasing an additional 6,115,853 shares in the last quarter. Northern Cross LLC boosted its stake in shares of Teva Pharmaceutical Industries by 14.0% in the 2nd quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock valued at $591,169,000 after purchasing an additional 2,184,172 shares in the last quarter. Finally, Nordea Investment Management AB boosted its stake in shares of Teva Pharmaceutical Industries by 2.5% in the 2nd quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock valued at $428,033,000 after purchasing an additional 311,894 shares in the last quarter. Hedge funds and other institutional investors own 56.76% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.watchlistnews.com/private-asset-management-inc-has-572000-holdings-in-teva-pharmaceutical-industries-ltd-teva/1639248.html.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) traded down 1.76% on Wednesday, reaching $14.48. 9,342,599 shares of the company’s stock traded hands. Teva Pharmaceutical Industries Ltd has a 12 month low of $14.30 and a 12 month high of $44.42. The firm’s 50-day moving average is $16.73 and its 200 day moving average is $26.05. The firm’s market cap is $14.71 billion.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). The company had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries had a negative net margin of 104.75% and a negative return on equity of 88.38%. The business’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period last year, the company posted $1.25 EPS. Equities analysts predict that Teva Pharmaceutical Industries Ltd will post $4.24 EPS for the current year.

TEVA has been the topic of a number of research analyst reports. Vetr upgraded shares of Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating and set a $32.27 price target on the stock in a research note on Wednesday, June 28th. Royal Bank Of Canada restated an “outperform” rating and issued a $37.00 price target (down from $38.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, July 17th. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries from a “strong sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and issued a $21.00 price target (down from $28.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 31st. Finally, BTIG Research upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 price target on the stock in a research note on Monday, September 11th. Five research analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $27.63.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.